2022
WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION
Leasure A, Acosta J, Schwartz A, Forman R, Sharma R, de Havenon A, Falcone G, Inzucchi S, Kernan W, Sheth K. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2022, 79: 1504. DOI: 10.1016/s0735-1097(22)02495-0.Peer-Reviewed Original Research
2019
19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.Peer-Reviewed Original ResearchRisk factor goalsCV deathDohme Corp.Boehringer Ingelheim PharmaceuticalsNovo Nordisk A/SJanssen PharmaceuticalsMerck SharpTakeda Pharmaceutical Company LimitedHazard ratioRisk factorsNovartis AGEli LillyACE inhibitor/ARB useCV risk factor controlConsistent cardiovascular benefitEMPA-REG OUTCOMECV risk factorsRisk factor controlPfizer Inc.Sanofi-AventisNon-smoking statusAdvisory PanelPost Hoc AnalysisCV risk increasesARB use
2018
Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c
WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.Peer-Reviewed Original ResearchControl of BPLow-density lipoprotein cholesterolRisk of incidentCV risk factorsBlood pressureBoehringer Ingelheim PharmaceuticalsRenal outcomesLipoprotein cholesterolRisk factorsJanssen PharmaceuticalsConventional CV risk factorsEMPA-REG OUTCOME trialBoehringer Ingelheim GmbHDiastolic blood pressureSystolic blood pressureEli LillyAbbVie IncEMPA groupSanofi GenzymeHazard ratioInhibitor empagliflozinRenoprotective roleTime-dependent covariatesOutcome trialsDohme Corp.